cincorlogo.jpg
CinCor Pharma to Present at Upcoming Investor Conferences
May 17, 2022 16:05 ET | CinCor Pharma Inc
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place...
cincorlogo.jpg
CinCor Reports First Quarter Financial Results and Provides Corporate Update
May 10, 2022 08:00 ET | CinCor Pharma Inc
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for...
cincorlogo.jpg
CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit
April 19, 2022 08:30 ET | CinCor Pharma Inc
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in...
cincorlogo.jpg
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 22, 2022 08:19 ET | CinCor Pharma Inc
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled...
cincorlogo.jpg
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
March 17, 2022 08:00 ET | CinCor Pharma Inc
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the...
cincorlogo.jpg
CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022
March 15, 2022 09:41 ET | CinCor Pharma Inc
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the...
cincorlogo.jpg
CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 03, 2022 09:15 ET | CinCor Pharma Inc
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment...
cincorlogo.jpg
CinCor Pharma Appoints June Lee to Its Board of Directors
January 13, 2022 08:00 ET | CinCor Pharma Inc
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee...
cincorlogo.jpg
CinCor Pharma Announces Pricing of Initial Public Offering
January 06, 2022 23:26 ET | CinCor Pharma Inc
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for...
cincorlogo.jpg
CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock
January 03, 2022 07:30 ET | CinCor Pharma Inc
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of...